share_log

VBI Vaccines Announces Presentation Of Physician-Initiated Compassionate Use Data Of 3-Antigen Hepatitis B Vaccine At 2022 International HBV Meeting; Presentation Was Monday, Sept. 19

Benzinga Real-time News ·  Sep 21, 2022 08:06

VBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that data from the physician-initiated compassionate use of VBI's 3-antigen hepatitis B vaccine in four adults chronically infected with hepatitis B virus (HBV) were presented in a poster session at the 2022 International HBV Meeting in Paris, France, on September 19.

Poster Presentation Details

  • Title: Therapeutic vaccination of chronically HBV infected patients with low-level of HBsAg using a combination of a third generation PreS/S vaccine (Sci-B-Vac) and a nucleoside analogue
  • Session: Poster Session I
  • Date: Monday, September 19, 2022
  • Presenter: Hedwig Roggendorf, M.D., Institute of Molecular Immunology and Experimental Oncology, University Hospital Rechts der Isar, Technical University of Munich
    • Event Website:
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment